Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...

The only actual available "test" for Alzheimer’s disease in younger people would be to check someone's APOE 4 levels, which ...

Guwahati: In a significant advancement for yak genomic science, the first-ever chromosome-level genome of the Indian yak (Bos ...

First-ever chromosome-level genome of the Indian yak revolutionizes breeding, conservation, and understanding of this vital ...

Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ...

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...

In cross-sectional models, greater sedentary time was tied to a smaller Alzheimer's disease-imaging MRI signature (β = ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

A new study links prolonged sedentary behavior to increased risk of cognitive decline and brain shrinkage associated with ...

“Our study showed that reducing sitting time could be a promising strategy for preventing neurodegeneration and subsequent ...